Kyorin’s route: an exclusive regional partner
Under the 5 January agreement, Lunatus Marketing & Consulting FZCO becomes the exclusive partner for Lasvic tablets in Saudi Arabia, the UAE, Kuwait, Bahrain, Qatar, Oman, Iraq, Lebanon and Jordan (Kyorin).
Kyorin will register as the marketing authorisation holder (MAH), the company that legally owns the licence, in each country. It will supply the product to Lunatus (Kyorin).
Lasvic (lascufloxacin) is an oral fluoroquinolone antibiotic for respiratory and ear, nose and throat infections. Kyorin says it is designed to concentrate in lung and ENT tissue while keeping exposure in the rest of the body low (Kyorin).
Lunatus, founded in 2003, describes itself as a turnkey partner covering regulatory work, marketing, sales, distribution and supply chain. Marubeni, the Japanese trading house, has invested in Lunatus since 2022 to bring more Japanese medicines and devices to the region (Kyorin).
The model keeps the licence in Japanese hands and outsources the market. Kyorin presents it as part of an out-licensing push under its medium-term business plan (Kyorin).
Sysmex’s route: a Saudi affiliate, headquarters and factory
Sysmex, the diagnostics maker, has taken the slower, heavier route. Its regional headquarters in Riyadh announced a memorandum of understanding (MoU) with the Saudi government for a diagnostic-reagent factory in the Kingdom and a logistics hub for the Middle East (Sysmex).
Sysmex’s release, dated 25 December 2025, calls it the first Japanese diagnostic-reagent factory in Saudi Arabia. The MoU also covers a platform to train local healthcare professionals (Sysmex).
Sysmex says it served Saudi customers for several decades through local partners before setting up a direct affiliate in 2022. It was one of the first Japanese companies in any sector to open a regional headquarters in Riyadh (Sysmex).
The sequence is partners first, then an affiliate, then local manufacturing. The release gives no investment value and no date for the factory.
Why Japanese pharmaceutical companies are looking at Saudi Arabia
Japan’s consul general in Jeddah, Daisuke Yamamoto, told Al-Eqtisadiah that Japanese companies had invested about SR23.6 billion ($6.28 billion) in Saudi Arabia. Eighteen had set up regional headquarters in the Kingdom, Arab News reported in September 2025 (Arab News).
He said 82 Japanese companies operated in Riyadh and 36 in Jeddah (Arab News). Those figures cover every sector, not only healthcare.
Saudi Arabia’s regional headquarters programme, launched in 2021, offers incentives that include a 30-year corporate tax exemption. JETRO’s Riyadh office and the Japan Cooperation Center for the Middle East in Jeddah help Japanese entrants understand the market (Arab News).
What the partners cannot tell you
A partner knows how to register a product and get it into pharmacies. It does not automatically know why a Gulf physician picks one antibiotic over another, or how a hospital lab director chooses an analyser platform.
For an antibiotic such as Lasvic, the open questions are about prescribing. Which infections do Gulf physicians treat with oral fluoroquinolones today? How do hospital antimicrobial stewardship teams, the committees that limit antibiotic use to slow resistance, treat a new entrant?
Do habits differ between Riyadh, Dubai and Kuwait City? These are research questions, not findings. The releases do not answer them.
For diagnostics, the questions are about procurement. Who in a Saudi hospital lab decides on a platform, and how much does reagent supply weigh against price? Our page on the in vitro diagnostics market in Saudi Arabia covers the regulatory side.
What is not known yet
Kyorin expects the impact on its fiscal year ending March 2026 to be negligible (Kyorin).
Neither company has published launch dates by country, a registration timetable, a factory start date or an investment value. Plans built on either deal should treat timing as unknown.
Our take
The partner route is quick and cheap to start, but it puts market knowledge one step away from the licence holder. The commitment route builds that knowledge in-house, but Sysmex spent decades selling through partners before it signed for a factory.
Most Japanese pharmaceutical companies will start with a partner. That makes independent research more important, not less. A headquarters in Japan approving a nine-country plan needs its own read on prescribers and payers, not only the partner’s forecast.
What Japanese pharmaceutical companies should research before filing
Three questions should be answered before the dossier is filed. The first is which countries go first. Unmet need and switching triggers can differ between the six GCC states, Iraq, Lebanon and Jordan.
The second is who decides. That means hospital pharmacy and therapeutics committees and, in Saudi Arabia, NUPCO, the national unified procurement company that runs public tenders. Our NUPCO tendering guide covers how those tenders work.
The third, for diagnostics, is what lab directors and procurement teams value when they choose a platform.
Country views help here: see healthcare market research in Saudi Arabia and healthcare market research in the UAE.
What to watch
Watch Lasvic registrations country by country, and any timeline for the Sysmex factory.
Watch, too, whether more Japanese companies follow Kyorin’s partner model or Sysmex’s regional-headquarters model.
What Japanese launch teams should do now
Decide early between a partner-led model and a direct affiliate, and research each country’s gatekeepers either way.
Run a short physician survey on unmet need and switching triggers in your therapy area before choosing launch countries.
Map formulary and tender decision-makers: hospital pharmacy and therapeutics committees, and NUPCO in Saudi Arabia. For diagnostics, interview lab directors and procurement teams on how they choose a platform.
Prepare Japanese-language briefings for headquarters alongside the English local reports.
If you are planning a Gulf launch from Japan and need physician or lab research before choosing a partner, BioNixus can scope it through our Middle East market research for Japanese companies. Delivery runs from our US, UK and Cairo teams with field teams across the region. We were founded in 2012 and have worked with 118 clients in 48 countries.
References
- KYORIN Pharmaceutical. KYORIN and Lunatus enter into distribution agreement for Lasvic tablets in nine Middle Eastern countries. 5 January 2026. Source.
- Sysmex Europe. Sysmex signs government MOU to establish first Japanese diagnostic reagent factory in Saudi Arabia. 25 December 2025. Source.
- Walid R. Japanese firms invest $6.3bn in Saudi Arabia, 18 set up regional HQs. Arab News. 7 September 2025. Source.
